Kaplan Meier survival curve analysis of the validation cohort of 75 NSCLC patients that underwent immunotherapies (MSK-NSCLC 2018) [15] showed that the median progression free survival (PFS) of NSCLC patients with TP53 truncating mutations (n=10) was 2.6 months compared to 7.56 months for patients with wild-type TP53 (n=32), but, the differences were not statistically significant (HR = 1.30, CI = 0.71-2.37, P = 0.402; Figure 2C). Here, TP53 is linked to non-small cell lung carcinoma.